Telesis Bio Analysis

Telesis Pink Sheet Analysis Notes

About 38.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.11. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Telesis Bio recorded a loss per share of 30.42. The entity had not issued any dividends in recent years. The firm had 1:18 split on the 9th of May 2024. Translate Bio, Inc., a clinical-stage messenger RNA therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company was founded in 2011 and is headquartered in Lexington, Massachusetts. Translate Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people.The quote for Telesis Bio is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Telesis Bio contact Eric Esser at 858 228 4115 or learn more at https://telesisbio.com.

Telesis Bio Investment Alerts

Telesis Bio Upcoming and Recent Events

Telesis Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.73 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Telesis Bio's market, we take the total number of its shares issued and multiply it by Telesis Bio's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Telesis Profitablity

The company has Profit Margin (PM) of (2.53) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (6.76) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $6.76.

Telesis Bio Insider Trading Activities

Telesis Bio Predictive Daily Indicators

Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how Telesis Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Telesis shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as Telesis Bio. By using and applying Telesis Pink Sheet analysis, traders can create a robust methodology for identifying Telesis entry and exit points for their positions.

Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

If you are still planning to invest in Telesis Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Telesis Bio's history and understand the potential risks before investing.